Skip to main content

Table 2 Clinical data, IGF-1, and IGFB-3 for Nordic walking group and low-intensity walking group

From: Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides

  Nordic walking Low-intensity walking Difference in change between groups at
at 15 weeks
Difference in change between groups at
at 30 weeks
  Baseline 15 weeks to 0 weeks 30 weeks to 0 weeks Baseline 15 weeks to 0 weeks 30 weeks to 0 weeks   
  Median (range) Diff
median (range)
P value a
Diff
median (range)
P value a
Median (range) Diff
median (range)
P value a
Diff
median (range)
P value a
P value b P value b
Pain threshold
kPa
199.2 (106.2 to 372.3) -6.6 (-84.6 to 75.6)
P = 0.454
13.9 (-109.2 to 94.1)
P = 0.278
215.4 (105.9 to 380.5) -13.7 (-102.1 to 36.8)
P = 0.031
-12.8 (-165.2 to 108.5)
P = 0.689
P = 0.169 P = 0.339
Pain
mm
70.5 (7 to 98) -0.5 (-40 to 25) P = 0.416 -1 (-39 to 53) P = 0.988 75 (10 to 92) -7 (-27 to 35) P = 0.067 -4 (-34 to 29) P = 0.218 P = 0.356 P = 0.432
6MWT
m
520 (381 to 660) 36.5 (-44 to 164.5) P < 0.001 29.3 (-150.5 to 145) P = 0.006 516 (428 to 656) 8 (-77 to 107) P = 0.183 -2 (-62.5 to 103) P = 0.520 P = 0.033 P = 0.049
IGF-1
ng/ml
4.3 (0 to 15.6) -0,2 (-11.4 to 28.7) P = 0.300 -0.7 (-12.7 to 1.7) P = 0.019 3.3 (0 to 35.7) -0.3 (-31.6 to 1.9) P = 0.148 -0.1 (-31.2 to 1.4) P = 0.109 P = 0.795 P = 0.570
IGFB3
ng/ml
1,449.2 (546.6 to 3,288.3) -57.4 (-1,524.7 to 1,846.6) P = 0.977 291.1 (-1,383.3 to 2,821.8) P = 0.426 1,680.9 (269.5 to 3,274.2) -33.5 (-1551.7 to 1,198.8) P = 0.881 242 (-1563 to 1,558.2) P = 0.796 P = 0.906 P = 0.872
  1. aWilcoxon signed rank test. bMann-Whitney U test. Median, range (min-max) for baseline, as well as median differences and P values at 15 and 30 weeks, are presented.